A Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by RedDress Ltd.
Information provided by (Responsible Party):
RedDress Ltd.
ClinicalTrials.gov Identifier:
First received: July 5, 2011
Last updated: September 11, 2014
Last verified: September 2014

The purpose of this study is to assess the safety of the RedDress Wound Care System (RD1) in patients Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

Condition Intervention Phase
Neuropathic Diabetic Ulcer - Foot
Device: RedDress Wound Care System (RD1)
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.

Resource links provided by NLM:

Further study details as provided by RedDress Ltd.:

Primary Outcome Measures:
  • Adverse event rate [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Adverse event rate will be calculated including serious adverse events (SAEs), adverse events (AEs) (including any lack of venous access events), and device-related adverse events (DRAEs) (safety population and ITT populations).

Secondary Outcome Measures:
  • Complication rate due to lack of venous access [ Time Frame: 10 weeks ] [ Designated as safety issue: Yes ]
    for all patients for all 10 visits involving RD1 procedure (ITT population)

  • Complication rate due to lack of venous access [ Time Frame: 10 ] [ Designated as safety issue: Yes ]
    for all patients for all 10 visits involving other procedure requiring venous access (ITT population)

  • Incidence of complete wound closure at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Defined as skin re-epithelialization without drainage or dressing requirements confirmed at 2 consecutive study visits 2 weeks apart) for DFU treated with RD1 (ITT population).

  • Percent reduction in wound size over 12 weeks (ITT population) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The data will also be plotted graphically week by week. Week 12 data will be used to recalculate sample size for the pivotal trial

  • Associations between lack of healing and patient/wound parameters (ITT population) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    A simple Cox regression will be used to examine each wound and patient parameter. Note: because sample size is very small, a full Cox regression cannot be undertaken.

Estimated Enrollment: 20
Study Start Date: May 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RedDress Wound Care System (RD1)
RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
Device: RedDress Wound Care System (RD1)
Weekly application. A blood based wound care treatment
Other Names:
  • RedDress Wound Care System
  • RD1

Detailed Description:

The investigational product, the RD1 kit, was designed to enable a care provider to create an in vitro blood clot from the patient's own blood at the point of care, in a safe and effective manner.

While many advanced modalities of treatment have been developed to heal chronic DFUs (as well as other types of chronic wounds), the vast majority have been approved for relatively non-severe wounds (e.g., Texas 1a/2a grades) and relatively healthy subjects in controlled clinical trials and typically exclude 25-75% of subjects who have several comorbidities and severe wounds. Moreover, when the results of such trials (and other trials of advanced modalities) have been subject to a systematic review, the strength of the evidence for their efficacy has been rated low or even insufficient to judge. Consequently, there is an urgent need for new technologies to be tested that can improve healing rates in all classes of chronic DFUs.

The study is a prospective, single group safety study, consisting of 20 subjects who will complete the study (note: if any patients are lost to follow-up or withdrawn, enrollment will increase to compensate for loss of these subjects). The subjects will receive 10 weekly RD1 applications and will be followed for additional 2 weeks. If the wound heal on weeks 11-12, additional 2 weeks follow up will be required. Subject data will be kept in each site's records.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is ≥18 years of age and has type 1 or 2 diabetes
  • Texas grade 1a or 2a wound located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts
  • Prior to inclusion of an ulcer in the study, each wound will be reviewed for eligibility by an independent assessor using a central online review process that includes images of the ulcer.
  • For patients with potentially multiple eligible DFUs, the biggest ulcer will be chosen as the study ulcer.
  • Ulcer size between 1 cm2 and 12 cm2 (post-debridement).
  • Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the first day of screening (i.e., day -14). Subjects will need to meet all inclusion criteria, including lack of ulcer healing until day 0.
  • Study ulcer separated from other ulcers by at least 2 cm.
  • Ulcer or affected limb free of clinical signs of infection. (Subjects with wound infection at the screening visit may be treated and re-screened for participation in the study after eradication of the infection).
  • Post-debridement, ulcer free of necrotic tissue.
  • Subject has adequate vascular perfusion of the affected limb, as defined by at least one of the following: (a) Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.2; (b) toe pressure (plethysmography) > 50 mm Hg; (c) TcPO2 > 40 mm Hg; or (d) skin perfusion pressure (SPP) > 30 mm Hg.
  • HbA1c ≤ 10.0% (diabetic patients)
  • Demonstrated adequate offloading regimen.
  • Subject must be willing to comply with the protocol including having blood drawn to create the RD1.
  • Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women).

Exclusion Criteria:

  • Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure ulcers.).
  • Presence of underlying osteomyelitis.
  • Patient with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection.
  • History of alcohol or substance abuse, within the previous 2 months
  • Subject has participated in another clinical trial involving a device or a systemically administered investigational study drug or treatment within 30 days of randomization visit.
  • Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic steroids, immunosuppressive therapy, autoimmune disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the foot, vascular surgery, angioplasty or thrombolysis).
  • Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled to receive during the study.
  • Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.
  • Wound on a patient who has a life expectancy of less than 12 months.
  • Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the informed consent form.
  • Cannot withdraw blood in the required amount (up to 10 mL per week) technically.
  • Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Patients who are taking coumadin, aspirin, or Plavix (clopidogrel) will not be excluded.
  • Hemoglobin anemia (< 10 g/dL).
  • Subject has a history of or any of the following intercurrent illnesses or conditions that would compromise the safety of the subject, or the normal wound healing process:

    • End stage renal disease
    • Immunosuppression.
    • Severe malnutrition
    • Liver disease
    • Scleroderma
    • Acquired immune deficiency disease (AIDS) or HIV positive
    • Connective tissue disorder
    • Exacerbation of sickle cell anemia
  • If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and standard of care phase, or if the ulcer area increases ≥ 30%, subject will be excluded.
  • Women who are pregnant or currently breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01396837

United States, Pennsylvania
ACMH Hospital - Snyder Institute for Vascular Health and Research Recruiting
Kittanning, Pennsylvania, United States, 16201
Contact: Serena    724-543-8893      
Principal Investigator: Dr. Keyur Patel, DO         
Sponsors and Collaborators
RedDress Ltd.
  More Information

No publications provided

Responsible Party: RedDress Ltd.
ClinicalTrials.gov Identifier: NCT01396837     History of Changes
Other Study ID Numbers: RD003
Study First Received: July 5, 2011
Last Updated: September 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by RedDress Ltd.:
Diabetic Foot Ulcer
Diabetic Ulcer
Diabetic Wound
Chronic Ulcer
Chronic Wound
Neuropathic Diabetic Foot Ulcer
Neuropathic DFU

Additional relevant MeSH terms:
Diabetic Foot
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Ulcer
Leg Ulcer
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on March 26, 2015